SYS6055

DRUG2 trials

Sponsors

Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd, Institute of Hematology & Blood Diseases Hospital, China

Conditions

Relapsed/Refractory Aggressive B-Cell LymphomaRelapsed/Refractory B-Cell Malignancies

Phase 1

Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory Aggressive B-Cell Lymphoma

Not yet recruitingNCT07476066

Beijing Kangchuanglian Biopharmaceutical Technology Research Co., LtdRelapsed/Refractory Aggressive B-Cell Lymphoma

Start: 2026-03-15End: 2031-03-15Target: 374Updated: 2026-03-17

Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies

Not yet recruitingNCT07493174

Institute of Hematology & Blood Diseases Hospital, ChinaRelapsed/Refractory B-Cell Malignancies

Start: 2026-04-15End: 2030-04-15Target: 86Updated: 2026-04-15